> “ Empowering genetically informed clinical decision making for the treatment of colorectal cancer. ”

Introduction

The BGI SENTIS™ Colorectal Cancer panel is a Next Generation Sequencing (NGS)-based genetic test that enables highly accurate detection of mutations across 7 genes associated with targeted therapy in colorectal cancer. The test provides a comprehensive molecular profiling of colorectal cancer to clinicians for genetically informed clinical decision making.

The Power of Knowing

BGI SENTIS™ Colorectal Cancer Genetic Testing

Advantages

Comprehensive	A single assay that detects most known mutations associated with the effectiveness of targeted therapy in colorectal cancer, providing molecular evidence for the consideration of 8 targeted therapies
Rigorous	Stringent QC process ensures robustness of the test

Advantages

GENE	TYPE OF MUTATION	HOTSPOT MUTATIONS
KRAS	SNV	G12(C,R,S,A,D,V); G13(C,R,S,A,D,V); Q61(K,P,L,R,H); K117N; A146(P,T,V)
NRAS	SNV	G12(C,R,S,A,D,V); G13(C,R,S,A,D,V); Q61(K,P,L,R,H); A146(P,T,V)
BRAF	SNV	V600E, V600G, V600A
PIK3CA	SNV	E542K, E545(K,Q,A,G,V), Q546(E,K,L,P,R), D549N, H1047(L,R)
PTEN	SNV, CNV	R159S, R223*, Copy Number Loss
EGFR	SNV, CNV	S492R, Copy Number Gain
NOTCH1	CNV	Copy Number Gain

Turnaround time

6 working days (from sample arriving at BGI lab to report)

Ordering Information

ITEM	CATALOG NO.
BGI SENTIS™ Colorectal	DX1278

Workflow



Contact your local BGI representative for more information or email **info@bgi-international.com**.

More information can also be found on our website.

www.bgi.com/global/

Published June 2017, version 1.0
For Research Use Only. Not for use in diagnostic procedures.
Testing services not currently available in the United States of America. Please contact a representative for regional availability.